Selecting Patients for Exclusive Permanent Implant Prostate Brachytherapy: The Experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital Group on 809 Patients

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 4, 2008, Pages 1042-1048

  Cosset, Jean Marc ^a   Flam, Thierry ^b   Thiounn, Nicolas ^c   Gomme, Stephanie ^a   Rosenwald, Jean Claude ^a   Asselain, Bernard ^a   Pontvert, Dominique ^a   Henni, Mehdi ^a   Debre, Bernard ^b   Chauveinc, Laurent ^a  

^a INSTITUT CURIE   (France)

^b Cochin Hospital ^*  (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Brachytherapy; Intermediate risk; Permanent implant; Prostate cancer

Indexed keywords

HOSPITALS; IODINE; PEELING; PIGMENTS; RISK ASSESSMENT;

125IODINE; BRACHYTHERAPY (BT); ELSEVIER (CO); GLEASON SCORE (GS); MONO THERAPY; PROSTATE BRACHYTHERAPY (PB); PROSTATE CANCER (CAP); PROSTATE SPECIFIC ANTIGEN (PSA); SEED IMPLANTATION;

HEALTH;

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRACHYTHERAPY; COHORT ANALYSIS; EXPERIENCE; GLEASON SCORE; HIGH RISK POPULATION; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; RELAPSE; STATISTICAL SIGNIFICANCE; SURVIVAL;

BRACHYTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PARIS; PATIENT SELECTION; PREVALENCE; PROSTATIC NEOPLASMS; PROSTHESES AND IMPLANTS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 45449109179     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.11.056     Document Type: Article

References (46)

1. Zelefsky M.J., Hollister T., Raben A., et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47 (2000) 1261-1266
2. Zelefsky M.J., Yamada Y., Cohen G.N., et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 65-70
3. Stone N.N., Stock R.G., and Unger P. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol 173 (2005) 803-807
4. Stock R.G., Cesaretti J.A., and Stone N.N. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 64 (2006) 810-816
5. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
6. Ash D., Al-Qaisieh B., Bottomley D., et al. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer. Radiother Oncol 79 (2006) 185-189
7. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67 (2007) 57-64
8. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
9. Guedea F., Aguilo F., Polo A., et al. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer. Radiother Oncol 80 (2006) 57-61
10. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
11. Merrick G.S., Wallner K.E., and Butler W.M. Patient selection for prostate brachytherapy: More myth than fact. Oncology (Williston Park) 18 (2004) 445-457
12. Merrick G.S., Butler W.M., Wallner K.E., et al. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL. Am J Clin Oncol 27 (2004) 611-615
13. Chauveinc L., Flam T., Solignac S., et al. Prostate cancer brachytherapy: Is real-time ultrasound-based dosimetry predictive of subsequent CT-based dose distribution calculation? A study of 450 patients by the Institut Curie/Hospital Cochin (Paris) Group. Int J Radiat Oncol Biol Phys 59 (2004) 691-695
14. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
15. Kuban D.A., Levy L.B., Potters L., et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 1487-1493
16. Thames H.D., Kuban D.A., DeSilvio M.L., et al. Increasing external beam dose for T1-T2 prostate cancer: Effect on risk groups. Int J Radiat Oncol Biol Phys 65 (2006) 975-981
17. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95 (2002) 281-286
18. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
19. Khaksar S.J., Langley S.E., Lovell D., et al. Interstitial low dose rate brachytherapy for prostate cancer-a focus on intermediate- and high-risk disease. Clin Oncol (R Coll Radiol) 18 (2006) 513-518
20. Merrick G.S., Wallner K.E., Butler W.M., et al. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer. BJU Int 98 (2006) 324-328
21. Lukka H. Prostate cancer: Risk categories and role of hormones and radiotherapy. Can J Urol 9 Suppl 1 (2002) 26-29
22. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A Phase III randomised trial. Lancet 360 (2002) 103-106
23. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
24. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
25. Stock R.G., Cahlon O., Cesaretti J.A., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352-1359
26. Fletcher S.G., Mills S.E., Smolkin M.E., et al. Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1092-1099
27. Stock R.G., Ho A., Cesaretti J.A., et al. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66 (2006) 389-394
28. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1048-1055
29. Vargas C.E., Martinez A.A., Boike T.P., et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a Phase I to II study. Int J Radiat Oncol Biol Phys 66 (2006) 416-423
30. Chin Y.S., Bullard J., Bryant L., et al. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol) 18 (2006) 474-479
31. Phan T.P., Syed A.M., Puthawala A., et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 177 (2007) 123-127
32. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199
33. Merrick G.S., Butler W.M., Wallner K.E., et al. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. W V Med J 101 (2005) 168-171
34. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 32-43
35. Merrick G.S., Wallner K.E., Butler W.M., et al. Permanent prostate brachytherapy: Is supplemental external-beam radiation therapy necessary?. Oncology (Williston Park) 20 (2006) 514-522
36. Brenner D.J., Curtis R.E., Hall E.J., et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88 (2000) 398-406
37. Brenner D.J. Induced second cancers after prostate-cancer radiotherapy: No cause for concern?. Int J Radiat Oncol Biol Phys 65 (2006) 637-639
38. Liauw S.L., Sylvester J.E., Morris C.G., et al. Second malignancies after prostate brachytherapy: Incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys 66 (2006) 669-673
39. Moon K., Stukenborg G.J., Keim J., et al. Cancer incidence after localized therapy for prostate cancer. Cancer 107 (2006) 991-998
40. Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98. Ann ICRP 35 iii-vi (2005) 3-50
41. Cosset J.M., Pinillos-Ashton L., and Mettler F. [The recommendations of the International Commission on Radiological Protection (ICRP) for high-dose-rate brachytherapy and for permanent prostatic implants]. Cancer Radiother 8 Suppl 1 (2004) S50-S55
42. Sengupta S., Davis B.J., Mynderse L.A., et al. Permanent prostate brachytherapy: Pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy. Urology 68 (2006) 810-814
43. Machtens S., Baumann R., Hagemann J., et al. Long-term results of interstitial brachytherapy (LDR-brachytherapy) in the treatment of patients with prostate cancer. World J Urol 24 (2006) 289-295
44. Frank S.J., Grimm P.D., Sylvester J.E., et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy 6 (2007) 2-8
45. Thompson I.M., Carroll P.R., and Carducci M.A. Recommendations for defining and treating high risk localized prostate cancer. J Urol 176 (2006) S6-S10 quiz S13-15
46. Stone N.N., Stock R.G., and Unger P. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation. Mol Urol 4 (2000) 163-170